Real-world data of the use of rivaroxaban in pediatric patients with hematologic malignancies

Leuk Lymphoma. 2024 Apr;65(4):538-540. doi: 10.1080/10428194.2023.2300719. Epub 2024 Jan 3.

Authors

Noémie Sultan¹, Marie-Claude Pelland-Marcotte², Meredith Remy³, Josette Champagne¹, Caroline Laverdière¹, Rochelle Winikoff¹, Thai Hoa Tran¹

Affiliations

¹ Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, CHU Sainte-Justine, Montréal, QC, Canada.
² Department of Pediatrics, CHU de Québec - Centre Mère-Enfant Soleil, Quebec City, QC, Canada.
³ Faculté de Médecine, Université Laval, Quebec City, QC, Canada.

PMID: 38170575
DOI: 10.1080/10428194.2023.2300719

No abstract available

MeSH terms

Anticoagulants / adverse effects
Atrial Fibrillation* / chemically induced
Child
Hematologic Neoplasms* / drug therapy
Hemorrhage / chemically induced
Humans
Rivaroxaban / adverse effects
Stroke*

Substances

Rivaroxaban
Anticoagulants